Loxo Oncology (LOXO) Posts Q3 Loss of 68c/Share

Loxo Oncology (NASDAQ: LOXO) reported Q3 EPS of ($0.68), $0.31 worse than the analyst estimate of ($0.37).

Recent Business Highlights

Appointed Chief Medical Officer and New Director to the Board

The Company recently announced the promotion of Jennifer Low, M.D., Ph.D. to Chief Medical Officer (CMO). In addition to being named CMO, Dr. Low continues to serve as the company's Executive Vice President, Research and Development. In conjunction with Dr. Low's promotion, Dr. Lori Kunkel, who previously served as Acting CMO, joined the Loxo Board of Directors as a non-employee director.

Announced Presentation of Pre-Clinical Data on LOXO-101 at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Loxo announced it will present pre-clinical data on the Company's pan-TRK inhibitor candidate, LOXO-101, in a poster session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Barcelona, Spain on November 18-21, 2014. The poster session is titled "LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancers" (Abstract #391). The date of the session is November 20, 2014 and the poster number is P171.

For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c